Table 1.
Clinical and laboratory characteristics of sickle cell disease patients
| n | Result | |
|---|---|---|
| Age, y | 399 | 12 (7-16) |
| Female sex, no. (%) | 399 | 191 (48) |
| Severe sickling phenotype, hemoglobin SS, Sβ0 thalassemia, or SDLA, no. (%) | 395 | 299 (76) |
| Hydroxyurea therapy, no. (%) | 397 | 150 (38) |
| Chronic transfusion program, no. (%) | 382 | 32 (8) |
| Oxygen saturation, % | 379 | 98 (97-99) |
| Change in oxygen saturation during 6-minute walk, % | 315 | 0 (−1-0) |
| Tricuspid regurgitation velocity, m/s | 372 | 2.3 (2.1-2.5) |
| Tricuspid regurgitation velocity, 2.5 m/s or higher, no. (%) | 372 | 81 (22) |
| Tricuspid regurgitation velocity, 2.6 m/s or higher, no. (%) | 372 | 41 (11) |
| Hemoglobin, g/L | 383 | 92 (81-106) |
| Mean corpuscular volume, fL | 377 | 84 (77-90) |
| White blood cells, ×109/L | 377 | 9.9 (7.5-13.2) |
| Absolute neutrophil count, 1000/μL | 375 | 4.6 (3.4-7.1) |
| Platelets, ×109/L | 377 | 381 (285-478) |
| Reticulocytes, ×109/L | 374 | 217 (147-315) |
| Lactate dehydrogenase, U/L | 356 | 377 (277-522) |
| Aspartate aminotransferase, U/L | 382 | 40 (29-53) |
| Total bilirubin, mg/dL | 382 | 2.2 (1.4-3.3) |
| Hemolytic component | 343 | 0.09 (−1.17 to 1.06) |
| Hemoglobin F, % | 199 | 9.0 (3.1-16.5) |
| Hemoglobin F 8% or higher, no. (%) | 199 | 112 (56) |
| Erythropoietin, IU/L | 371 | 55 (30-96) |
Results are in median and interquartile range unless otherwise indicated.